Corbus Pharmaceuticals Data on CRB-601 avβ8 Blocking Antibody Accepted for Presentation at the America Association for Cancer Research Annual Meeting

NORWOOD, Mass., March 14, 2023 /PRNewswire/ — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that an abstract highlighting pre-clinical data for CRB-601, its avβ8 blocking antibody, has been accepted for…

Leave a Reply

Your email address will not be published. Required fields are marked *